Date:	--/--/-- --:--:--
Event Id:	E5L3L470O
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	TECH
Updated:	--/--/-- --:--:--
Purchase Price Per Share:
Price Per Share Currency:	USD
News References:	https://www.prnewswire.com/news-releases/bio-techne-shareholders-approve-acquisition-by-merck-kgaa-darmstadt-germany-302887726.html

Action Notes

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price. The proposed transaction has been approved by Bio-Techne's Board of Directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, and is expected to close by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including receipt of required regulatory approvals and approval by Bio-Techne shareholders.8/20 On 9/23 at special meeting of TECH shareholders, they will vote on merger agreement.